论文部分内容阅读
目的观察DC/CIK细胞治疗中、晚期恶性肿瘤的临床安全性和耐受性。方法采集10例以原发性肝癌为主的中、晚期恶性肿瘤患者外周血单个核细胞,经体外诱导产生DC和CIK细胞,分次经外周静脉回输给患者,观察其输注后不良反应、生活质量(KPS评分)及生化相关指标的变化。结果经DC/CIK细胞治疗后,绝大多数患者的精神、食欲、体力较前明显好转,生活质量评分较前提高,毒性不良反应轻微,肝、肾功能检测均无明显改变。结论应用DC/CIK细胞治疗以原发性肝癌为主的中、晚期恶性肿瘤临床安全性良好,无严重不良反应,可提高患者的生活质量,改善临床症状,具有一定的临床使用价值。
Objective To observe the clinical safety and tolerability of DC / CIK cells in the treatment of middle and advanced malignant tumors. Methods Peripheral blood mononuclear cells (PBMC) from 10 patients with primary hepatocellular carcinoma who were predominantly malignant tumors were collected. DCs and CIK cells were induced in vitro. The patients were transfused by peripheral vein and the adverse reaction was observed , Quality of life (KPS score) and biochemical related indicators. Results After treatment with DC / CIK cells, the mental, appetite and physical performance of the overwhelming majority of patients were significantly improved compared with those before. The quality of life score was higher than before. The adverse toxic reactions were mild and the liver and renal function tests showed no significant changes. Conclusion The application of DC / CIK cells in the treatment of middle and advanced stage primary malignant tumor of liver cancer has good clinical safety and no serious adverse reactions, which can improve patients’ quality of life and improve clinical symptoms, and has certain clinical value.